Canada markets open in 3 hours 17 minutes

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.13-0.58 (-5.97%)
At close: 04:00PM EST
8.52 -0.61 (-6.68%)
Pre-Market: 04:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous Close9.71
Open9.28
Bid0.00 x 1200
Ask0.00 x 800
Day's Range8.13 - 9.40
52 Week Range8.13 - 25.18
Volume1,985,969
Avg. Volume22,550
Market Cap67.163M
Beta (5Y Monthly)0.44
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    Delcath Systems, Inc. Announces Positive Phase 3 FOCUS Trial Results for Hepzato™ in Liver-Dominant Metastatic Ocular Melanoma, Including Initial Survival Data Analysis

    On final analysis of the primary overall response (ORR) endpoint, HEPZATO further exceeded the predefined threshold for success with a median duration of response of 14 months While overall survival data continues to mature, a Hazard Ratio (HR) analysis of survival at 12-months yielded a statistically significant advantage for HEPZATO over a Best Alternative Care (BAC) arm [HR=0.37, p=0.01] in patients who received one or more treatments HEPZATO had statistically significant improvements over BA

  • GlobeNewswire

    Delcath Systems Provides Speaker List for Dec 2, 2021 Investor Update Meeting

    Focus Trial Data and Future Development Plans to be Discussed by Management and KOLsNEW YORK, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today its agenda and distinguished speaker list for a comprehensive Investor Update Meeting taking place Thursday, December 2nd , from 10:00am ET – 1:30pm EST. The event will focus on the company’s US product candida

  • GlobeNewswire

    Delcath Systems Announces Third Quarter 2021 Results

    NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2021. Recent Business Highlights During and since the third quarter Delcath: Entered a debt facility with Avenue Venture Opportunities Fund, L.P. providing up to $20 million with an initial $15 million fund